Modification of PEG reduces the immunogenicity of biosynthetic gas vesicles

Yuanyuan Wang, Meijun Fu, Yaozhang Yang, Jinghan Zhang, Zhaomeng Zhang, Jingling Xiao, Yingjie Zhou, Fei YanFrontiers in Bioengineering and Biotechnology 2023 · DOI

TL;DR

Researchers have successfully "cloaked" biosynthetic gas vesicles (GVs)—nature's nanobubbles—using a polyethylene glycol (PEG) coating. This modification significantly reduces immune system recognition and clearance, extending their circulation time and dramatically improving their performance as ultrasound contrast agents for tumor imaging.

What Problem Does This Paper Address?

Ultrasound is a cornerstone of medical imaging, but it has a size problem. Traditional contrast agents are microbubbles (1–8 µm), which are too large to escape blood vessels and reach extravascular tissues like tumor cells.

Enter Gas Vesicles (GVs): protein-shelled nanostructures produced by certain bacteria and archaea (like Halobacterium NRC-1). Because they are nanoscale, they can penetrate deep into tumors. However, there is a catch: GVs are foreign proteins. When injected into a mammal, the immune system—specifically the Reticuloendothelial System (RES)—identifies them as invaders and clears them rapidly. This high "immunogenicity" limits their effectiveness and raises safety concerns. This paper investigates whether a "stealth" coating of polyethylene glycol (PEG) can solve these issues.

Methods

The team extracted GVs from Halobacterium NRC-1 and modified their surface using a standard chemical technique called EDC/NHS coupling to attach PEG-amine (5 kDa) to the carboxyl groups on the GV protein shell.

To evaluate the impact, they used a multi-tiered approach:

  • Characterization: They used Transmission Electron Microscopy (TEM) to ensure the GVs stayed intact and Dynamic Light Scattering (DLS) to measure size changes.
  • In Vitro Assays: They tested how easily macrophages (immune "eater" cells) could gobble up the GVs and whether the GVs triggered the maturation of dendritic cells (the "alarm" cells of the immune system).
  • In Vivo Studies: Using C57BL/6 mice, they tracked the biodistribution of fluorescently labeled GVs and performed real-time ultrasound imaging on MB49 tumor models to compare the contrast duration and intensity between plain GVs and PEG-GVs.

Datasets

As a biological study, the "datasets" consist of experimental results from specific cell lines and animal models:

  • Cell Lines: RAW264.7 (murine macrophages), DC 2.4 (dendritic cells), MB49 (bladder cancer cells for tumor models), and bEnd.3 (endothelial cells for toxicity testing).
  • Animal Models: C57BL/6 mice were used for all in vivo biodistribution, immunogenicity, and imaging experiments.

Key Insights and Ideas

  • Neutralizing the Charge: Plain GVs have a strong negative surface charge (Zeta potential of -35.53 mV). PEGylation shielded this charge, bringing the potential to a nearly neutral -0.78 mV. This is crucial because highly charged particles are often "red flags" for immune cells.
  • Escaping the "Eaters": PEGylation created a hydration layer that physically hindered macrophages from engulfing the GVs. In cell cultures, the uptake of PEG-GVs was significantly lower than that of plain GVs.
  • Phenotype Shifting: The study found that plain GVs pushed macrophages toward the M1 phenotype (pro-inflammatory/aggressive). PEG modification mitigated this response, suggesting a much lower risk of systemic inflammation.
  • Extended "On-Air" Time: Because they weren't cleared as quickly by the liver and spleen, PEG-GVs remained in the tumor area longer, providing a more stable and intense ultrasound signal compared to the rapid "washout" seen with plain GVs.

Key Results

  • Reduced Immunogenicity: In dendritic cells, the expression of maturation markers (CD80/CD86) was significantly lower in the PEG-GV group (~25%) compared to the plain GV group (42.5%).
  • Improved Imaging: In tumor-bearing mice, PEG-GVs produced a stronger ultrasound contrast signal that persisted well beyond the 60-second mark, whereas plain GV signals declined rapidly after injection.
  • Lower Liver Accumulation: Fluorescence imaging showed that PEG-GVs had significantly lower accumulation in the liver at 4 and 24 hours post-injection compared to plain GVs.
  • Safety Profile: No significant toxicity was observed. Blood biochemical markers (ALT, AST, BUN, CREA) remained within normal ranges, and organ histology showed no pathological damage after 16 days of treatment.

Limitations and Future Work

The authors acknowledge a few areas for further exploration:

  • Optimization of PEG: The study only used 5 kDa PEG. Future research could investigate whether different PEG chain lengths or grafting densities further optimize the "stealth" effect.
  • Active Targeting: These PEG-GVs rely on passive accumulation in tumors. The next logical step is to attach specific ligands (like antibodies or peptides) to the PEG tips to actively target specific cancer biomarkers.
  • Long-term Immunogenicity: While the 14-day safety profile looked excellent, the effects of chronic, long-term repeated exposure to biosynthetic GVs still need to be fully understood before clinical translation.

Summary updated

Abstract

Nanobubbles have received great attention in ultrasound molecular imaging due to their capability to pass through the vasculature and reach extravascular tissues. Recently, gas vesicles (GVs) from archaea have been reported as acoustic contrast agents, showing great potential for ultrasound molecular imaging. However, the immunogenicity and biosafety of GVs has not yet been investigated. In this study, we examined the immune responses and biosafety of biosynthetic GVs and polyethylene glycol (PEG)-modified GVs (PEG-GVs) in vivo and in vitro. Our findings suggest that the plain GVs showed significantly stronger immunogenic response than PEG-GVs. Less macrophage clearance rate of the RES and longer circulation time were also found for PEG-GVs, thereby producing the better contrast imaging effect in vivo. Thus, our study demonstrated the PEG modification of biosynthetic GVs from Halobacterium NRC-1 is helpful for the future application of GVs in molecular imaging and treatment.
BibTeX
@inproceedings{wang2023modification,
  author = {Yuanyuan Wang and Meijun Fu and Yaozhang Yang and Jinghan Zhang and Zhaomeng Zhang and Jingling Xiao and Yingjie Zhou and Fei Yan},
  title = {{Modification of PEG reduces the immunogenicity of biosynthetic gas vesicles}},
  booktitle = {Frontiers in Bioengineering and Biotechnology},
  year = {2023},
  doi = {10.3389/fbioe.2023.1128268},
}
Figure